Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo clínico para avaliar ianalumabe em participantes com esclerose cutânea sistêmica difusa

6 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo multicêntrico randomizado, duplo-cego, de grupo paralelo e controlado por placebo para avaliar a eficácia, segurança e tolerabilidade do ianalumabe em participantes com esclerose cutânea sistêmica difusa

The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo

Visão geral do estudo

Status

Ativo, não recrutando

Descrição detalhada

The study consists of the following periods:

  • Screening Period, with a duration of up to 6 weeks;
  • Treatment Period 1, with a duration of 52 weeks;
  • Treatment Period 2 (Open-label treatment), with a duration of 52 weeks;
  • Post-treatment Follow-up Period, with a duration of at least 20 weeks post last dose and up to 2 years.

Tipo de estudo

Intervencional

Inscrição (Real)

203

Estágio

  • Fase 2

Acesso expandido

Disponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 13353
        • Novartis Investigative Site
    • Bavaria
      • Würzburg, Bavaria, Alemanha, 97080
        • Novartis Investigative Site
      • Caba, Argentina, C1015ABO
        • Novartis Investigative Site
      • Caba, Argentina, C1427CCL
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1221ADC
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40150-150
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasil, 80030-110
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-074
        • Novartis Investigative Site
    • São Paulo
      • Sao Jose Rio Preto, São Paulo, Brasil, 15090-000
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 04038-002
        • Novartis Investigative Site
      • Leuven, Bélgica, 3000
        • Novartis Investigative Site
      • Beijing, China, 100191
        • Novartis Investigative Site
      • Tianjin, China, 300052
        • Novartis Investigative Site
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Novartis Investigative Site
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Novartis Investigative Site
    • Zhejiang
      • Ningbo, Zhejiang, China, 315016
        • Novartis Investigative Site
      • Bogotá, Colômbia, 110231
        • Novartis Investigative Site
      • Medellín, Colômbia, 050034
        • Novartis Investigative Site
    • Antioquia
      • Medellín, Antioquia, Colômbia, 050001
        • Novartis Investigative Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colômbia, 110111
        • Novartis Investigative Site
      • Bogota, Cundinamarca, Colômbia, 110221
        • Novartis Investigative Site
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colômbia, 760012
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 04763
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 06273
        • Novartis Investigative Site
    • Seoul
      • Seoul, Seoul, Coréia do Sul, 03080
        • Novartis Investigative Site
      • Barcelona, Espanha, 08041
        • Novartis Investigative Site
      • Madrid, Espanha, 28009
        • Novartis Investigative Site
    • Andalusia
      • Málaga, Andalusia, Espanha, 29009
        • Novartis Investigative Site
    • Arizona
      • Mesa, Arizona, Estados Unidos, 85202
        • Arizona Arthritis and Rheumatology Research PLLC
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • UCLA
      • Newport Beach, California, Estados Unidos, 92663
        • Hoag Hospital
    • Florida
      • Clearwater, Florida, Estados Unidos, 33765
        • Clinical Res Of W Florida
      • Cooper City, Florida, Estados Unidos, 33024
        • GNP Research
      • Plantation, Florida, Estados Unidos, 33324
        • IRIS Research and Development
      • Sarasota, Florida, Estados Unidos, 34239
        • Sarasota Arthritis Res Ctr
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Hospitals
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Uni Of Michigan Health System
    • New York
      • New York, New York, Estados Unidos, 10021
        • Hospital for Special Surgery
    • Tennessee
      • Jackson, Tennessee, Estados Unidos, 38305
        • West Tennessee Research Institute
    • Texas
      • Bellaire, Texas, Estados Unidos, 77401
        • Novel Research LLC
      • Frisco, Texas, Estados Unidos, 75035
        • Arthritis and Rheumatology Ins
      • Houston, Texas, Estados Unidos, 77054
        • Prolato Clinical Research Center
      • Le Mans, França, 72000
        • Novartis Investigative Site
      • Lille, França, 59037
        • Novartis Investigative Site
      • Paris, França, 75014
        • Novartis Investigative Site
      • Toulouse, França, 31054
        • Novartis Investigative Site
      • Alexandroupoli, Grécia, 681 00
        • Novartis Investigative Site
      • Athens, Grécia, 115 27
        • Novartis Investigative Site
      • Athens, Grécia, 115 21
        • Novartis Investigative Site
      • Budapest, Hungria, 1083
        • Novartis Investigative Site
    • Baranya
      • Pécs, Baranya, Hungria, 7623
        • Novartis Investigative Site
    • AN
      • Ancona, AN, Itália, 60020
        • Novartis Investigative Site
    • MI
      • Milan, MI, Itália, 20100
        • Novartis Investigative Site
      • Rozzano, MI, Itália, 20089
        • Novartis Investigative Site
    • MO
      • Modena, MO, Itália, 41124
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Itália, 27100
        • Novartis Investigative Site
    • RM
      • Roma, RM, Itália, 00168
        • Novartis Investigative Site
    • VR
      • Verona, VR, Itália, 37134
        • Novartis Investigative Site
      • Hiroshima, Japão, 7348551
        • Novartis Investigative Site
      • Ishikawa, Japão, 9208641
        • Novartis Investigative Site
      • Kyoto, Japão, 6068507
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 4578510
        • Novartis Investigative Site
      • Toyoake, Aichi-ken, Japão, 4701192
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japão, 2360004
        • Novartis Investigative Site
    • Saitama
      • Iruma-gun, Saitama, Japão, 3500495
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo-ku, Tokyo, Japão, 1138603
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japão, 1628666
        • Novartis Investigative Site
    • Toyama
      • Toyama, Toyama, Japão, 9300194
        • Novartis Investigative Site
      • Kuala Lumpur, Malásia, 59100
        • Novartis Investigative Site
    • Kuala Lumpur
      • Cheras, Kuala Lumpur, Malásia, 56000
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, México, 31000
        • Novartis Investigative Site
    • Jalisco
      • Guadalajara, Jalisco, México, 44650
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, México, 11850
        • Novartis Investigative Site
    • Nuevo León
      • Monterrey, Nuevo León, México, 64460
        • Novartis Investigative Site
      • Bydgoszcz, Polônia, 85-168
        • Novartis Investigative Site
      • Warsaw, Polônia, 00-874
        • Novartis Investigative Site
      • Vila Nova de Gaia, Portugal, 4434-502
        • Novartis Investigative Site
      • Bristol, Reino Unido, BS10 5NB
        • Novartis Investigative Site
      • London, Reino Unido, NW3 2QG
        • Novartis Investigative Site
      • Bangkok, Tailândia, 10400
        • Novartis Investigative Site
    • THA
      • Khon Kaen, THA, Tailândia, 40002
        • Novartis Investigative Site
      • Changhua, Taiwan, 50006
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 833
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turquia (Türkiye), 34093
        • Novartis Investigative Site
      • Ho Chi Minh City, Vietnã, 700000
        • Novartis Investigative Site
    • VNM
      • Ho Chi Minh City, VNM, Vietnã, 700000
        • Novartis Investigative Site
      • Graz, Áustria, 8036
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, Índia, 682018
        • Novartis Investigative Site
    • Maharashtra
      • Mumbai, Maharashtra, Índia, 400078
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Índia, 110060
        • Novartis Investigative Site
    • New Delhi
      • New Delhi, New Delhi, Índia, 110029
        • Novartis Investigative Site
    • Rajasthan
      • Jaipur, Rajasthan, Índia, 302004
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  • Male and female participants >= 18 and =< 70 years (at the time of the screening visit).

  • Diagnosis of systemic sclerosis, as defined by the 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria for SSc (van den Hoogen et al 2013) and meet the dcSSc subset classification according to LeRoy (LeRoy 1988)

  • Disease duration of =< 60 months (defined as time from the first non-Raynaud phenomenon manifestation, e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea)

  • mRSS units of >= 15 and =< 45 at the time of the screening visit

  • Active disease that meets at least one of the following criteria at screening:

    • Disease duration of =< 18 months defined as time from the first non-Raynaud phenomenon manifestation
    • Increase in mRSS of >= 3 units compared with the most recent assessment performed within the previous 6 months
    • Involvement of one new body area and an increase in mRSS of >= 2 units compared with the most recent assessment performed within the previous 6 months
    • Involvement of two new body areas within the previous 6 months
    • Elevated acute phase reactants (ESR) >= 30 mm/hr or high-sensitivity C-reactive protein (hsCRP) >= 6 mg/L)
    • Presence of SSc-interstitial lung disease (ILD) and ATA autoantibody positivity
    • Modified EUSTAR disease activity index (mDAI) ≥ 2.5
  • Participant must be positive for at least one of the following autoantibodies:

    • anti-topoisomerase I (ATA) (also known as anti-SCL-70)
    • anti-RNA polymerase III (anti-RNAP3)
    • anti-nuclear antibody (ANA) (≥ 1:80) Participants who are positive only for ANA (while being negative for both ATA /anti-RNAP3) will be limited to 30% of the overall randomized study population.

Key Exclusion Criteria:

  • Rheumatic disease other than dcSSc, including limited cutaneous disease (lcSSc) or sine scleroderma at the screening visit. Secondary Sjogren's disease and scleroderma myopathy are not exclusionary.
  • Positive anti-centromere antibody (ACA+) without positive ATA or anti-RNAP3 autoantibody result at the screening visit
  • Previous improvement (decrease) in mRSS > 10 units
  • Pulmonary disease with FVC ≤ 50% of predicted or diffusing capacity of the lung for carbon monoxide (DLCO, corrected for hemoglobin) ≤ 40% of predicted at the screening visit
  • WHO Functional Class 3 or higher assessment for pulmonary arterial hypertension (PAH, as defined on right heart catheterization), receiving IV therapy for PAH or evidence of other moderately severe pulmonary disease
  • Participants treated with cyclophosphamide within 12 weeks prior to Baseline.
  • Prior use of a B-cell depleting therapy other than ianalumab (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks prior to randomization, or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower).
  • Treatment with biologic agents, such as intravenous immunoglobulin or monoclonal antibodies, including marketed drugs, within 12 weeks or 5 half-lives (whichever is longer) prior to baseline visit, unless explicitly allowed in inclusion criteria.
  • Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit.
  • Use of anti-fibrotic agents including colchicine, D-penicillamine, pirfenidone, or tyrosine kinase inhibitors (e.g., nintedanib, nilotinib, imatinib, dasatinib) in the 4 weeks prior to baseline visit. Patients with SSc-ILD requiring antifibrotics for management of ILD during the study, as per investigator judgement, should be excluded.
  • Previous treatment with chlorambucil, bone marrow transplantation or total lymphoid irradiation.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment and for 6 months after stopping study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: VAY736 (Ianalumab)

Treatment Period 1:

Ianalumab subcutaneous (s.c.) injection as defined in the protocol

Treatment Period 2:

Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

subcutaneous (s.c.) injection as defined in the protocol

Outros nomes:
  • VAY736
Comparador de Placebo: Placebo

Treatment Period 1:

Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol

Treatment Period 2:

Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol

subcutaneous (s.c.) injection as defined in the protocol

Outros nomes:
  • VAY736

Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
3/5 rCRISS25 response
Prazo: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, in achieving 3/5 Revised Composite Response Index in Systemic Sclerosis 25 (rCRISS25) response at Week 52

Week 52

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in FVC% predicted at Week 52
Prazo: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in percent-predicted forced vital capacity (FVC%) at Week 52

Week 52
Change from baseline in mRSS at Week 52
Prazo: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in modified Rodnan Skin Score (mRSS) at Week 52

Week 52
Change from baseline in HAQ-DI at Week 52
Prazo: Week 52

To demonstrate the superiority of ianalumab, compared to placebo, on change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52

Week 52
Ianalumab concentrations in serum during treatment and Follow-up Period
Prazo: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 108, Week 112, Week 116, Week 120, Week 124 and Week 208

To assess the pharmacokinetics of ianalumab

Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 108, Week 112, Week 116, Week 120, Week 124 and Week 208
Incidence and titer of anti-drug (ianalumab) antibodies (ADAs) in serum over time
Prazo: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 124, Week 208

To evaluate the immunogenicity of ianalumab

Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, Week 64, Week 76, Week 88, Week 104, Week 124, Week 208
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Up to Week 208

The distribution of adverse events for ianalumab will be done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs) through the monitoring of relevant clinical and laboratory safety parameters.

Up to Week 208

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de outubro de 2024

Conclusão Primária (Estimado)

30 de julho de 2027

Conclusão do estudo (Estimado)

31 de julho de 2034

Datas de inscrição no estudo

Enviado pela primeira vez

17 de junho de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de junho de 2024

Primeira postagem (Real)

24 de junho de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever